Welcome to our dedicated page for Janux Therapeutics SEC filings (Ticker: JANX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Janux Therapeutics filings document a clinical-stage biopharmaceutical issuer developing tumor-activated immunotherapies through the TRACTr, TRACIr and ARM platforms. Recent 8-K reports furnish financial results and business updates covering clinical programs such as JANX007, JANX014, JANX011 and JANX008, as well as cash-position commentary and pipeline prioritization.
The company’s regulatory record also includes a material definitive agreement for the Bristol Myers Squibb collaboration, with license, development, commercialization, milestone and royalty terms. Proxy and governance filings document director elections, board-classification matters, executive compensation, pay-versus-performance disclosure and officer or director changes.